Huadong Medicine Group
Huadong Medicine Co., Ltd. (Stock Code: 000963.SZ) is headquartered in Hangzhou, Zhejiang Province, and was listed on the Shenzhen Stock Exchange in December 1999. Huadong Medicine has been repeatedly recognized among the “Top 50 Best Listed Companies in Asia-Pacific” by Forbes, ranked among the “Top 100 Most Valuable Listed Companies in China’s Main Board Market”, and has been included for many consecutive years in the Fortune China 500 list selected by Fortune China. It was also selected among the Top 50 Global Pharmaceutical Companies in 2025 by the U.S. magazine Pharmaceutical Executive.
The company spans the entire pharmaceutical industry chain, focusing on four core segments: pharmaceutical development, pharmaceutical distribution, medical aesthetics, and microbiology. Today, it stands as a leading pharmaceutical enterprise specializing in innovative R&D, manufacturing, sales, and marketing.
Huadong Medicine specializes in the research, development, production, and sales of treatments for specialty, chronic, and rare diseases. We have established a comprehensive pharmaceutical manufacturing and quality assurance system, with a core product pipeline focusing on chronic kidney disease, immune disorders, oncology, endocrinology and digestive system diseases. Our portfolio includes several leading clinical drugs in the domestic market, with multiple products having obtained international registration certifications. We collaborate with global innovators to better serve patients in China. Through internal drug development, external partnerships, and strategic collaborations, we focus on three core therapeutic areas: oncology, endocrinology, and autoimmune diseases.
Oncology
Huadong Medicine is dedicated to building a world-leading platform for innovative oncology drug development. We have established a pipeline of targeted small molecule drugs, ADCs, antibodies, and PROTACs, with over a dozen globally innovative drugs. For instance, in collaboration with ImmunoGen in the United States, we have developed ELAHERE®, the first ADC drug of its kind, intended for platinum-resistant ovarian cancer. Additionally, we have invested in, acquired, and incubated multiple biotech companies with cutting-edge technology both domestically and internationally, creating a unique ADC global R&D ecosystem to drive the development of differentiated ADC therapies.
Endocrinology
We have established a comprehensive pipeline of innovative and differentiated solutions targeting key therapeutic areas in diabetes, with 20+ drugs commercialized and in-development. Specifically, Huadong Medicine has developed a broad GLP-1 product line that includes multiple dosage forms—both oral and injectable—as well as long-acting and multi-target global innovations and biosimilars. Our liraglutide injection has received NMPA approval for diabetes and for obesity or overweight indications, making it the first domestically produced option in China for these indications.
Autoimmunity
Huadong Medicine has become one of the most comprehensive pharmaceutical companies in China in the field of autoimmune diseases. We currently have a pipeline of over 20 innovative products, including biologics and small-molecule drugs, under development. At the same time, we are expanding into topical formulations, having established a dedicated R&D platform for topical preparations. We are steadily advancing innovation in topical and complex formulations, covering a wide range of indications. To date, 10 topical products are either in development or have entered commercialization. The company has built a fully integrated capability encompassing the R&D, registration, production, and commercialization of topical formulations.
As a leading regional pharmaceutical distributor, Huadong Medicine has ranked among China’s top 10 pharmaceutical wholesalers for consecutive years. We operate across three major segments—pharmaceuticals, medical devices, and herbal medicines—and continue to strengthen our core competitiveness through innovative services such as specialized pharmaceutical logistics featuring cold-chain, vaccines, and specialty drugs, as well as our proprietary pharmaceutical e-commerce platform and private-label offerings. The company operates three self-owned regional logistics centers in northern Zhejiang (Hangzhou), central Zhejiang (Jinhua), and southern Zhejiang (Wenzhou), along with 13 logistics warehouses, with a total storage area exceeding 190,000 square meters. The pharmaceutical segment offers comprehensive advantages across the entire product range and all distribution channels, enabling seamless coordination between in-hospital and out-of-hospital supply, as well as integrated distribution and agency services. The medical device segment expands specialized agency services through large-scale distribution capabilities. The herbal medicine segment encompasses the entire value chain—from base-level cultivation and decoction piece processing to automated decoction services and the sale of proprietary functional products.
Sinclair, headquartered in the United Kingdom with nearly 50 years of scientific heritage, serves as our global operating platform in the field of aesthetic healthcare. Guided by a comprehensive aesthetic healthcare strategy and driven by technological innovation, Sinclair has built a strong global portfolio of aesthetic healthcare products. We operate six major R&D and manufacturing centers across the United Kingdom, the Netherlands, France, Switzerland, Spain, Bulgaria, and Israel. Sinclair has established a differentiated and complementary product portfolio designed to address unmet clinical needs for high-efficacy, high-quality, long-lasting, natural-looking, and minimally invasive treatments. Empowered by advanced technology and access to industry-leading insights, Sinclair has developed a mature commercial and marketing network in North America and the European Union, as well as in Brazil, Mexico, Colombia, the United Arab Emirates, Hong Kong (China), and South Korea. Leveraging a robust global operating platform, our commercial presence now extends to over 80 countries and regions worldwide.
Huadong Medicine has a solid foundation and extensive expertise in microbiology, successfully developing and manufacturing a range of microbial-based drugs that meet industry-leading standards. We focus on two strategic priorities: innovation in synthetic biology and upgrading the biopharmaceutical industry, with key advancement across four core business segments: xRNA, specialty APIs & intermediates, wellness & biomaterials, and animal health.
Our core R&D cluster includes: CME Huadong Microbial R&D Center, Huadong Synthetic Biology Industrial Technology Research Institute, Huida Biotech, Huixin Biotech, and Shengji Biomaterials. We operate seven industrialization bases located in: Xiangfuqiao (Hangzhou), Qiantang New District, Jiuyang (Jiangsu), Meiqi (Hubei), Meihua (Anhui), Huaren (Wuhu), and Nannong Animal Health.